Table 1.
Patient Characteristics at Baseline
| Characteristics | Data |
|---|---|
| Number of patients | 28 |
| Sex (male/female) | 6/22 |
| Age (years) | 45 (± 12) |
| BMI (kg/m2) | 28.2 (± 4.8) |
| Dose of LABA (μg/day salmeterol equivalents) | 136 (± 35) |
| Dose of ICS (μg/day fluticasone equivalents) | 1158 (± 501) |
| Number of patients on maintenance use of OCS | 9 |
| Dose of oral prednisone (mg/day) in OCS users | 13 (± 6) |
| Number of patients on omalizumab | 3 |
| Pre-short-acting bronchodilator FEV1 (% predicted) | 86 (± 24) |
| Post-short-acting bronchodilator FEV1 (% predicted) | 100 (± 19) |
| FEV1 reversibility (%) | 14 (± 15) |
| PC20 (mg/mL) | 0.35 (0.03–2.92 IQR) (N=27) |
| FeNO | 17.5 (12.8–41.8 IQR) (N=25) |
| Number of patients with a positive skin prick test | 15 (54%) |
| Total serum IgE (kU/L) | 51.95 (17.05–210.25 IQR) |
| Blood eosinophil count (109/L) | 0.14 (0.06–0.29 IQR) |
Notes: Data are presented as absolute numbers, mean ± standard deviation) or median with interquartile range (IQR).
Abbreviations: BMI, body mass index; LABA, long-acting β2-agonist; ICS, Inhaled corticosteroids; OCS, oral corticosteroids; FEV1, forced expiratory volume in 1 second; PC20, methacholine provocation test; FeNO, fraction exhaled nitric oxide; IgE, Immunoglobulin E.